The AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) on May 31 announced the presentation of results from a first-in-human Phase 1 study of AV-203, AVEO’s ErbB3 (HER3) inhibitory antibody candidate. Among the results, the study established a recommended Phase 2 dose of AV-203, demonstrated good tolerability and promising early signs of activity, and reached the maximum planned dose of AV-203 monotherapy. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) weekly performance is 1.87%. On last trading day company shares ended up $1.09. Analysts mean target price for the company is $1.67. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) distance from 50-day simple moving average is -17.67%.
Omeros Corporation (Nasdaq:OMER) announced that the U.S. Food and Drug Administration (FDA) has approved Omidria™ (phenylephrine and ketorolac injection) 1%/0.3% for use during cataract surgery or intraocular lens replacement (ILR) to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative pain. Omeros Corporation (NASDAQ:OMER) shares advanced 1.20% in last trading session and ended the day on $11.83. its return on assets is -170.50%. Omeros Corporation (NASDAQ:OMER) quarterly performance is -8.44%.
Inovio Pharmaceuticals, Inc. (nysemkt:INO) announced that its previously announced 1-for-4 reverse stock split shall become effective at 5 P.M., Thursday, June 5, 2014, and trading of the Company’s common stock on a post-reverse split basis shall commence on Friday, June 6, 2014. The common stock will continue to trade under the symbol “INO.”Inovio Pharmaceuticals Inc (NYSEMKT:INO) shares moved down -4.89% in last trading session and was closed at $2.14, while trading in range of $2.13-$2.32. Inovio Pharmaceuticals Inc (NYSEMKT:INO) year to date performance is -26.21%.
Investment analysts at Maxim Group cut their price objective on shares of ImmunoCellular Therapeutics (NASDAQ:IMUC) from $12.00 to $4.00 in a note issued to investors on Monday. The firm currently has a “buy” rating on the stock.ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) ended the last trading day at $1.15. Company weekly volatility is calculated as 12.25% and price to cash ratio as 2.66. ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) showed a negative weekly performance of -12.21%.
Analysts at Janney Montgomery Scott initiated coverage on shares of NPS Pharmaceuticals in a research note on Thursday. They set a “buy” rating and a $37.00 price target on the stock. NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) net profit margin is -7.10% and weekly performance is 21.64%. On last trading day company shares ended up $32.60. Analysts mean target price for the company is $39.73. NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) distance from 50-day simple moving average is 20.72%.